Literature DB >> 9535248

Streptococcus pneumoniae capsular polysaccharide-diphtheria toxoid conjugate vaccine is immunogenic in early infancy and able to induce immunologic memory.

H Ahman1, H Käyhty, H Lehtonen, O Leroy, J Froeschle, J Eskola.   

Abstract

BACKGROUND: Pneumococcal polysaccharide vaccines are not protective against the most common pneumococcal infections in infancy. The importance of pneumococcal diseases and emerging antimicrobial resistance emphasize the need for prophylaxis.
METHODS: Pneumococcal conjugate vaccine, containing capsular polysaccharides from serotypes 6B, 14, 19F and 23F conjugated to diphtheria toxoid (PncD), was given to 75 infants at 2, 4 and 6 months of age. Three dosages (1, 3 or 10 microg of each) were used. A placebo group of 49 infants received physiologic saline. Children were given a booster dose of either polysaccharide or conjugate vaccine at 14 months of age; the placebo group received conjugate vaccine. Antibody concentrations were determined with an enzyme immunoassay.
RESULTS: The highest dose induced the strongest response after primary immunization, but booster response was greatest in the group primed with the lowest dose. Polysaccharide and conjugate vaccines induced booster responses of the same magnitude. At 24 and 36 months of age the antibody concentrations were similar in children who had received the PncD in infancy and in children immunized at 14 months of age only.
CONCLUSIONS: The PncD conjugate vaccine is immunogenic and able to induce immunologic memory.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9535248     DOI: 10.1097/00006454-199803000-00008

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  24 in total

1.  Contribution of serotype-specific IgG concentration, IgG subclasses and relative antibody avidity to opsonophagocytic activity against Streptococcus pneumoniae.

Authors:  M Anttila; M Voutilainen; V Jäntti; J Eskola; H Käyhty
Journal:  Clin Exp Immunol       Date:  1999-12       Impact factor: 4.330

2.  Pneumococcal Pneumonia.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

3.  CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization.

Authors:  Richard Malley; Krzysztof Trzcinski; Amit Srivastava; Claudette M Thompson; Porter W Anderson; Marc Lipsitch
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-21       Impact factor: 11.205

4.  Concentration and high avidity of pneumococcal antibodies persist at least 4 years after immunization with pneumococcal conjugate vaccine in infancy.

Authors:  Nina Ekström; Heidi Ahman; Arto Palmu; Sinikka Grönholm; Terhi Kilpi; Helena Käyhty
Journal:  Clin Vaccine Immunol       Date:  2013-05-08

5.  Priming of immunological memory by pneumococcal conjugate vaccine in children unresponsive to 23-valent polysaccharide pneumococcal vaccine.

Authors:  Markus A Rose; Ralf Schubert; Nicola Strnad; Stefan Zielen
Journal:  Clin Diagn Lab Immunol       Date:  2005-10

6.  Protective levels of polysaccharide-specific maternal antibodies may enhance the immune response elicited by pneumococcal conjugates in neonatal and infant mice.

Authors:  Margret Y Richter; Havard Jakobsen; Jean-François Haeuw; Ultan F Power; Ingileif Jonsdottir
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

Review 7.  Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

8.  Are the enzyme immunoassays for antibodies to pneumococcal capsular polysaccharides serotype specific?

Authors:  A Soininen; G van den Dobbelsteen; L Oomen; H Käyhty
Journal:  Clin Diagn Lab Immunol       Date:  2000-05

9.  Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial.

Authors:  F M Russell; J R Carapetis; A Balloch; P V Licciardi; A W J Jenney; L Tikoduadua; L Waqatakirewa; J Pryor; J Nelson; G B Byrnes; Y B Cheung; M L K Tang; E K Mulholland
Journal:  Vaccine       Date:  2010-03-04       Impact factor: 3.641

10.  Reduction of antibody response to an 11-valent pneumococcal vaccine coadministered with a vaccine containing acellular pertussis components.

Authors:  Ron Dagan; David Goldblatt; James R Maleckar; Mansour Yaïch; Juhani Eskola
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.